Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
Journey Medical Corporation (“Journey Medical” or “the Company”)(Nasdaq: DERM), a commercial-stage pharmaceutical company thatprimarily focuses on the selling and marketing of U.S. Food andDrug Administration (“FDA”)-approved prescription pharmaceuticalproducts for the treatment of dermatological conditions, announcedtoday that Claude Maraoui, Co-Founder, President and ChiefExecutive Officer, will participate in a fireside chat at theAlliance Global Partners’ (A.G.P.) Virtual Healthcare CompanyShowcase on Tuesday, May 21, 2024, at 1:00 p.m. ET.
Please click here to register for theconference.
A replay of the fireside chat will be availableshortly after the conference on the News and Events page of theInvestors section of Journey Medical’s website,www.journeymedicalcorp.com, for approximately 30 days after themeeting.
About Journey MedicalCorporation
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is acommercial-stage pharmaceutical company that primarily focuses onthe selling and marketing of FDA-approved prescriptionpharmaceutical products for the treatment of dermatologicalconditions through its efficient sales and marketing model. TheCompany currently markets seven branded and two generic productsthat help treat and heal common skin conditions. The JourneyMedical team comprises industry experts with extensive experiencein developing and commercializing some of dermatology’s mostsuccessful prescription brands. Journey Medical is located inScottsdale, Arizona and was founded by Fortress Biotech, Inc.(Nasdaq: FBIO). Journey Medical’s common stock is registered underthe Securities Exchange Act of 1934, as amended, and it filesperiodic reports with the U.S. Securities and Exchange Commission(“SEC”). For additional information about Journey Medical, visitwww.journeymedicalcorp.com.
Company Contact:
Jaclyn Jaffe
(781) 652-4500
ir@jmcderm.com
Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
From Apr 2024 to May 2024
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
From May 2023 to May 2024
 | {{bbMessage.M_Alias}}{{bbMessage.MSG_Date}}{{bbMessage.HowLongAgo}}{{bbMessage.MSG_ID}}{{bbMessage.MSG_Subject}} |
Loading Messages....
News
Loading Messages....
`,data() {return {tabs: [] };},created() {this.tabs = this.$children;},methods: {selectTab(selectedTab) {this.tabs.forEach(tab => {tab.isActive = (tab.name == selectedTab.name);});}}});Vue.component('tab', {template: `
`,props: {name: { required: true },selected: { default: false}},data() {return {isActive: false};},computed: {href() {return '#' + this.name.toLowerCase().replace(/ /g, '-');}},mounted() {this.isActive = this.selected;}});Vue.component('newslist', {template: `
FEATURED
•{{ article.source }} • {{ article.date}} {{article.time}}
`,props: {source: { required: true },rawarticles: { required: true },limit: { default: 12 }},methods: {processData: function(articles){if(articles.length > this.limit){articles = articles.slice(0, this.limit);}this.articles = articles;this.loaded = true;Vue.nextTick(function(){});},stripRedudancies: function(articles){return _.uniqBy(articles, "headline");}},data() {return {loaded: false,articles: []};},mounted() {this.processData(this.rawarticles);}});new Vue({el: '#nw-news-widget',data: {loaded: false,availableTabs: {"Press Releases": [{"headline":"Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements","link":"https:\/\/ih.advfn.com\/common\/newswire\/ct\/MjE5Ng==","timestamp":1715954400,"date":"Fri May 17, 2024 ","time":"10:00 AM (1 day ago)","isPromoted":true},{"headline":"Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b\/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)","short_text":"MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (\u201cAvenue\u201d or the \u201cCompany\u201d), a specialty pharmaceutical company focused on the development and commercialization...","one_line_short_text":"MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (\u201cAvenue\u201d or the \u201cCompany\u201d), a specialty pharmaceutical company...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/fortress-biotech-FBIO\/stock-news\/93868409\/avenue-therapeutics-announces-last-patient-last-vi","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1715862618,"date":"Thu May 16, 2024 ","time":"8:30 AM (2 days ago)","full_date":"May 16, 2024 8:30 AM","post_time":"May 16 2024","article_id":93868409,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Fortress Biotech to Participate in the Alliance Global Partners\u2019 (A.G.P.) Virtual Healthcare Company Showcase","short_text":"MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (\u201cFortress\u201d), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term...","one_line_short_text":"MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (\u201cFortress\u201d), an innovative biopharmaceutical company focused on...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/fortress-biotech-FBIO\/stock-news\/93868121\/fortress-biotech-to-participate-in-the-alliance-gl","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1715860838,"date":"Thu May 16, 2024 ","time":"8:00 AM (2 days ago)","full_date":"May 16, 2024 8:00 AM","post_time":"May 16 2024","article_id":93868121,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights","short_text":"Fortress\u2018 late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs in the next 12 months and potentially a fourth BLA filing as early as 2025...","one_line_short_text":"Fortress\u2018 late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs in the next 12 months and...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/fortress-biotech-FBIO\/stock-news\/93860485\/fortress-biotech-reports-first-quarter-2024-financ","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1715804129,"date":"Wed May 15, 2024 ","time":"4:15 PM (3 days ago)","full_date":"May 15, 2024 4:15 PM","post_time":"May 15 2024","article_id":93860485,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Journey Medical Corporation to Participate in the Alliance Global Partners\u2019 (A.G.P.) Virtual Healthcare Company Showcase","short_text":"SCOTTSDALE, Ariz., May 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (\u201cJourney Medical\u201d or \u201cthe Company\u201d) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily...","one_line_short_text":"SCOTTSDALE, Ariz., May 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (\u201cJourney Medical\u201d or \u201cthe Company\u201d) (Nasdaq: DERM), a...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/fortress-biotech-FBIO\/stock-news\/93860039\/journey-medical-corporation-to-participate-in-the","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1715803312,"date":"Wed May 15, 2024 ","time":"4:01 PM (3 days ago)","full_date":"May 15, 2024 4:01 PM","post_time":"May 15 2024","article_id":93860039,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights","short_text":"\u2013\u00a0Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 \u2013 MIAMI, May 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI...","one_line_short_text":"\u2013\u00a0Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 \u2013 MIAMI, May 15, 2024 (GLOBE NEWSWIRE...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/fortress-biotech-FBIO\/stock-news\/93856486\/avenue-therapeutics-reports-first-quarter-2024-fin","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1715776200,"date":"Wed May 15, 2024 ","time":"8:30 AM (3 days ago)","full_date":"May 15, 2024 8:30 AM","post_time":"May 15 2024","article_id":93856486,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation","short_text":"Helocyte, a majority-owned subsidiary of Fortress Biotech, is developing Triplex for the prevention and treatment of cytomegalovirus in multiple transplant indications, as well as HIV Clinical...","one_line_short_text":"Helocyte, a majority-owned subsidiary of Fortress Biotech, is developing Triplex for the prevention and treatment of cytomegalovirus in multiple...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/fortress-biotech-FBIO\/stock-news\/93845376\/fortress-biotech-announces-first-patient-dosed-in","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1715689800,"date":"Tue May 14, 2024 ","time":"8:30 AM (4 days ago)","full_date":"May 14, 2024 8:30 AM","post_time":"May 14 2024","article_id":93845376,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights","short_text":"New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first quarter ended March 31, 2024 were $13.0 million, a...","one_line_short_text":"New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/fortress-biotech-FBIO\/stock-news\/93837912\/journey-medical-corporation-reports-first-quarter","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1715630507,"date":"Mon May 13, 2024 ","time":"4:01 PM (5 days ago)","full_date":"May 13, 2024 4:01 PM","post_time":"May 13 2024","article_id":93837912,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024","short_text":"SCOTTSDALE, Ariz., May 07, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (\u201cJourney Medical\u201d or the \u201cCompany\u201d) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the...","one_line_short_text":"SCOTTSDALE, Ariz., May 07, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (\u201cJourney Medical\u201d or the \u201cCompany\u201d) (Nasdaq: DERM), a...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/fortress-biotech-FBIO\/stock-news\/93791589\/journey-medical-corporation-to-announce-first-quar","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1715085010,"date":"Tue May 07, 2024 ","time":"8:30 AM (2 weeks ago)","full_date":"May 7, 2024 8:30 AM","post_time":"May 07 2024","article_id":93791589,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Mustang Bio Announces Closing of $4 Million Public Offering","short_text":"WORCESTER, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (\u201cMustang\u201d or the \u201cCompany\u201d) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today\u2019s...","one_line_short_text":"WORCESTER, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (\u201cMustang\u201d or the \u201cCompany\u201d) (Nasdaq: MBIO), a clinical-stage...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/fortress-biotech-FBIO\/stock-news\/93770277\/mustang-bio-announces-closing-of-4-million-public","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1714680067,"date":"Thu May 02, 2024 ","time":"4:01 PM (2 weeks ago)","full_date":"May 2, 2024 4:01 PM","post_time":"May 02 2024","article_id":93770277,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer","short_text":"SCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (\u201cJourney Medical\u201d or \u201cthe Company\u201d) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily...","one_line_short_text":"SCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (\u201cJourney Medical\u201d or \u201cthe Company\u201d) (Nasdaq: DERM), a...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/fortress-biotech-FBIO\/stock-news\/93762283\/journey-medical-corporation-appoints-joseph-benesc","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1714593690,"date":"Wed May 01, 2024 ","time":"4:01 PM (2 weeks ago)","full_date":"May 1, 2024 4:01 PM","post_time":"May 01 2024","article_id":93762283,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Mustang Bio Announces Pricing of $4 Million Public Offering","short_text":"WORCESTER, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (\u201cMustang\u201d or the \u201cCompany\u201d) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today\u2019s...","one_line_short_text":"WORCESTER, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (\u201cMustang\u201d or the \u201cCompany\u201d) (Nasdaq: MBIO), a clinical-stage...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/fortress-biotech-FBIO\/stock-news\/93738741\/mustang-bio-announces-pricing-of-4-million-public","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1714435207,"date":"Mon Apr 29, 2024 ","time":"8:00 PM (3 weeks ago)","full_date":"April 29, 2024 8:00 PM","post_time":"April 29 2024","article_id":93738741,"source_id":"globe","media_url":null,"press_release":true}],"All News": [{"headline":"Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements","link":"https:\/\/ih.advfn.com\/common\/newswire\/ct\/MjE5Ng==","timestamp":1715954400,"date":"Fri May 17, 2024 ","time":"10:00 AM (1 day ago)","isPromoted":true},{"headline":"Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b\/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)","short_text":"MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (\u201cAvenue\u201d or the \u201cCompany\u201d), a specialty pharmaceutical company focused on the development and commercialization...","one_line_short_text":"MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (\u201cAvenue\u201d or the \u201cCompany\u201d), a specialty pharmaceutical company...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/fortress-biotech-FBIO\/stock-news\/93868409\/avenue-therapeutics-announces-last-patient-last-vi","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1715862618,"date":"Thu May 16, 2024 ","time":"8:30 AM (2 days ago)","full_date":"May 16, 2024 8:30 AM","post_time":"May 16 2024","article_id":93868409,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Fortress Biotech to Participate in the Alliance Global Partners\u2019 (A.G.P.) Virtual Healthcare Company Showcase","short_text":"MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (\u201cFortress\u201d), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term...","one_line_short_text":"MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (\u201cFortress\u201d), an innovative biopharmaceutical company focused on...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/fortress-biotech-FBIO\/stock-news\/93868121\/fortress-biotech-to-participate-in-the-alliance-gl","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1715860838,"date":"Thu May 16, 2024 ","time":"8:00 AM (2 days ago)","full_date":"May 16, 2024 8:00 AM","post_time":"May 16 2024","article_id":93868121,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights","short_text":"Fortress\u2018 late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs in the next 12 months and potentially a fourth BLA filing as early as 2025...","one_line_short_text":"Fortress\u2018 late-stage pipeline continues to advance and may generate up to three regulatory approvals on NDAs and BLAs in the next 12 months and...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/fortress-biotech-FBIO\/stock-news\/93860485\/fortress-biotech-reports-first-quarter-2024-financ","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1715804129,"date":"Wed May 15, 2024 ","time":"4:15 PM (3 days ago)","full_date":"May 15, 2024 4:15 PM","post_time":"May 15 2024","article_id":93860485,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Journey Medical Corporation to Participate in the Alliance Global Partners\u2019 (A.G.P.) Virtual Healthcare Company Showcase","short_text":"SCOTTSDALE, Ariz., May 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (\u201cJourney Medical\u201d or \u201cthe Company\u201d) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily...","one_line_short_text":"SCOTTSDALE, Ariz., May 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (\u201cJourney Medical\u201d or \u201cthe Company\u201d) (Nasdaq: DERM), a...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/fortress-biotech-FBIO\/stock-news\/93860039\/journey-medical-corporation-to-participate-in-the","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1715803312,"date":"Wed May 15, 2024 ","time":"4:01 PM (3 days ago)","full_date":"May 15, 2024 4:01 PM","post_time":"May 15 2024","article_id":93860039,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights","short_text":"\u2013\u00a0Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 \u2013 MIAMI, May 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI...","one_line_short_text":"\u2013\u00a0Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 \u2013 MIAMI, May 15, 2024 (GLOBE NEWSWIRE...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/fortress-biotech-FBIO\/stock-news\/93856486\/avenue-therapeutics-reports-first-quarter-2024-fin","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1715776200,"date":"Wed May 15, 2024 ","time":"8:30 AM (3 days ago)","full_date":"May 15, 2024 8:30 AM","post_time":"May 15 2024","article_id":93856486,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation","short_text":"Helocyte, a majority-owned subsidiary of Fortress Biotech, is developing Triplex for the prevention and treatment of cytomegalovirus in multiple transplant indications, as well as HIV Clinical...","one_line_short_text":"Helocyte, a majority-owned subsidiary of Fortress Biotech, is developing Triplex for the prevention and treatment of cytomegalovirus in multiple...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/fortress-biotech-FBIO\/stock-news\/93845376\/fortress-biotech-announces-first-patient-dosed-in","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1715689800,"date":"Tue May 14, 2024 ","time":"8:30 AM (4 days ago)","full_date":"May 14, 2024 8:30 AM","post_time":"May 14 2024","article_id":93845376,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights","short_text":"New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first quarter ended March 31, 2024 were $13.0 million, a...","one_line_short_text":"New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/fortress-biotech-FBIO\/stock-news\/93837912\/journey-medical-corporation-reports-first-quarter","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1715630507,"date":"Mon May 13, 2024 ","time":"4:01 PM (5 days ago)","full_date":"May 13, 2024 4:01 PM","post_time":"May 13 2024","article_id":93837912,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024","short_text":"SCOTTSDALE, Ariz., May 07, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (\u201cJourney Medical\u201d or the \u201cCompany\u201d) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the...","one_line_short_text":"SCOTTSDALE, Ariz., May 07, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (\u201cJourney Medical\u201d or the \u201cCompany\u201d) (Nasdaq: DERM), a...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/fortress-biotech-FBIO\/stock-news\/93791589\/journey-medical-corporation-to-announce-first-quar","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1715085010,"date":"Tue May 07, 2024 ","time":"8:30 AM (2 weeks ago)","full_date":"May 7, 2024 8:30 AM","post_time":"May 07 2024","article_id":93791589,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Mustang Bio Announces Closing of $4 Million Public Offering","short_text":"WORCESTER, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (\u201cMustang\u201d or the \u201cCompany\u201d) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today\u2019s...","one_line_short_text":"WORCESTER, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (\u201cMustang\u201d or the \u201cCompany\u201d) (Nasdaq: MBIO), a clinical-stage...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/fortress-biotech-FBIO\/stock-news\/93770277\/mustang-bio-announces-closing-of-4-million-public","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1714680067,"date":"Thu May 02, 2024 ","time":"4:01 PM (2 weeks ago)","full_date":"May 2, 2024 4:01 PM","post_time":"May 02 2024","article_id":93770277,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer","short_text":"SCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (\u201cJourney Medical\u201d or \u201cthe Company\u201d) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily...","one_line_short_text":"SCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (\u201cJourney Medical\u201d or \u201cthe Company\u201d) (Nasdaq: DERM), a...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/fortress-biotech-FBIO\/stock-news\/93762283\/journey-medical-corporation-appoints-joseph-benesc","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1714593690,"date":"Wed May 01, 2024 ","time":"4:01 PM (2 weeks ago)","full_date":"May 1, 2024 4:01 PM","post_time":"May 01 2024","article_id":93762283,"source_id":"globe","media_url":null,"press_release":true},{"headline":"Mustang Bio Announces Pricing of $4 Million Public Offering","short_text":"WORCESTER, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (\u201cMustang\u201d or the \u201cCompany\u201d) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today\u2019s...","one_line_short_text":"WORCESTER, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (\u201cMustang\u201d or the \u201cCompany\u201d) (Nasdaq: MBIO), a clinical-stage...","link":"https:\/\/ih.advfn.com\/stock-market\/NASDAQ\/fortress-biotech-FBIO\/stock-news\/93738741\/mustang-bio-announces-pricing-of-4-million-public","source":"GlobeNewswire Inc.","source_logo":"\/common\/images\/news-sources\/globe.png","tags":[],"timestamp":1714435207,"date":"Mon Apr 29, 2024 ","time":"8:00 PM (3 weeks ago)","full_date":"April 29, 2024 8:00 PM","post_time":"April 29 2024","article_id":93738741,"source_id":"globe","media_url":null,"press_release":true}],"Preferred Contributors": ""}},created: function () {this.loaded = true;Vue.nextTick(function(){});}});});
More News Articles
